[Development of intelligent DDS technologies].

T Okano

Home/Archive/PubMed

PubMed · 8277588

[Development of intelligent DDS technologies].

T Okano

View original source ↗Export metadata ↓

Abstract

Recently, biologically active therapeutic peptides have been artificially synthesized by genetic engineering techniques. These peptides are easily degraded under physiological conditions and also encounter absorption problems due to their high molecular weight. Hence, they cannot be utilized effectively in conventional dosage forms. For such active agents, new types of DDS must be developed to deliver the drug effectively to the target site (targeted, site-specific delivery) and release drug when drug is required (temporal control) in addition to conventional rate-controlling systems. To realize such drug release systems, it is important to construct a system where drug itself senses an environmental stimuli and responds to appropriately control drug release. Such systems are described as "intelligent DDS", as distinguished from conventional DDS.

Explore related subjects

Drug Delivery Systems Peptides Physical Stimulation Stimulation, Chemical English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

T Okano. 1993. [Development of intelligent DDS technologies].. https://pubmed.ncbi.nlm.nih.gov/8277588/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Microparticles and nanoparticles for drug delivery.

Particulate drug delivery systems have become important in experimental pharmaceutics and clinical medicine. The distinction is often made between micro- and nanoparticles, being particles with dimensions best described in micrometers and nanometers respectively. That size difference entails real differences at many levels, from formulation to in vivo usage. Here I will discuss those differences and provide examples of applications, for local and systemic drug delivery. I will outline a number of challenges of interest in particulate drug delivery.

Drug Delivery Systems↗

PubMed2007

On the suitability of nanocrystalline ferrites as a magnetic carrier for drug delivery: functionalization, conjugation and drug release kinetics.

Superparamagnetic nickel ferrite nanoparticles functionalized with polyvinyl alcohol, polyethylene oxide and polymethacrylic acid (PMAA) polymers and subsequently conjugated with doxorubicin anti-cancer drug are studied for their use as a magnetic carrier for drug delivery. Fourier transform infrared spectroscopy enabled examination of the ability of the nanoparticles to be functionalized with polymers and conjugated with doxorubicin drug. The functionalized polymer-coated nanocrystalline nickel ferrites retain the magnetic characteristics of non-functionalized nanocrystalline nickel ferrites (superparamagnetism, absence of hysteresis, remanence and coercivity at room temperature), encouraging their application as a magnetic carrier for drug delivery. The PMAA-coated nanoferrites are demonstrated as being a potentially superior magnetically targeted drug carrier based on FTIR results and drug release kinetics in the absence and presence of an external magnetic field.

Drug Delivery Systems↗

PubMed2007

Internalization of novel non-viral vector TAT-streptavidin into human cells.

BACKGROUND: The cell-penetrating peptide derived from the Human immunodeficiency virus-1 transactivator protein Tat possesses the capacity to promote the effective uptake of various cargo molecules across the plasma membrane in vitro and in vivo. The objective of this study was to characterize the uptake and delivery mechanisms of a novel streptavidin fusion construct, TAT47-57-streptavidin (TAT-SA, 60 kD). SA represents a potentially useful TAT-fusion partner due to its ability to perform as a versatile intracellular delivery vector for a wide array of biotinylated molecules or cargoes. RESULTS: By confocal and immunoelectron microscopy the majority of internalized TAT-SA was shown to accumulate in perinuclear vesicles in both cancer and non-cancer cell lines. The uptake studies in living cells with various fluorescent endocytic markers and inhibiting agents suggested that TAT-SA is internalized into cells efficiently, using both clathrin-mediated endocytosis and lipid-raft-mediated macropinocytosis. When endosomal release of TAT-SA was enhanced through the incorporation of a biotinylated, pH-responsive polymer poly(propylacrylic acid) (PPAA), nuclear localization of TAT-SA and TAT-SA bound to biotin was markedly improved. Additionally, no significant cytotoxicity was detected in the TAT-SA constructs. CONCLUSION: This study demonstrates that TAT-SA-PPAA is a potential non-viral vector to be utilized in protein therapeutics to deliver biotinylated molecules both into cytoplasm and nucleus of human cells.

Drug Delivery Systems↗